Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stef Meers

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
Cancers|July 14, 2023
Disease Perception Is Correlated with Health-Related Quality of Life in Patients Suffering from Myelodysplastic Syndromes: Results of the Belgian Be-QUALMS StudyBert Heyrman, Stef Meers, Ann De Becker, et al.
Clinical Hematology International|October 13, 2022
Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) StudyAnn Janssens, Zwi N Berneman, Fritz Offner, et al.
Ejhaem|October 17, 2024
Real-life data of luspatercept in lower-risk myelodysplastic syndromes advocate new research objectivesBert Heyrman, Stef Meers, Sélim Sid, et al.
Bone Marrow Transplantation|February 6, 2025
Life 2.0: a comprehensive cross-sectional profiling of long-term allogeneic hematopoietic cell transplantation survivors compared to a matched general population cohortHélène Schoemans, Kathy Goris, Steffen Fieuws, et al.
Annals of Hematology|May 4, 2021
Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registryTimothy Devos, Violaine Havelange, Koen Theunissen, et al.
The Lancet. Haematology|December 8, 2023
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trialAmer M Zeidan, Kiyoshi Ando, Odile Rauzy, et al.
Hematology (Amsterdam, Netherlands)|August 14, 2025
Real-world outcomes in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia treated with ponatinib - final 6-year results from a Belgian registryTimothy Devos, Dries Deeren, Koen Theunissen, et al.
Journal of Geriatric Oncology|August 10, 2025
Prospective comparison between geriatric assessment and clinical evaluation in 200 newly diagnosed older adults with multiple myelomaJolien Raddoux, Cindy Kenis, Anneleen Vanhellemont, et al.
Acta Clinica Belgica|February 23, 2017
Results from the Belgian mantle cell lymphoma registryVibeke Vergote, Ann Janssens, Marc André, et al.
Hemasphere|October 31, 2022
Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA ReportJon Salmanton-García, Francesco Marchesi, Andreas Glenthøj, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Cancers|July 14, 2023
Disease Perception Is Correlated with Health-Related Quality of Life in Patients Suffering from Myelodysplastic Syndromes: Results of the Belgian Be-QUALMS StudyBert Heyrman, Stef Meers, Ann De Becker, et al.
Clinical Hematology International|October 13, 2022
Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) StudyAnn Janssens, Zwi N Berneman, Fritz Offner, et al.
Ejhaem|October 17, 2024
Real-life data of luspatercept in lower-risk myelodysplastic syndromes advocate new research objectivesBert Heyrman, Stef Meers, Sélim Sid, et al.
Bone Marrow Transplantation|February 6, 2025
Life 2.0: a comprehensive cross-sectional profiling of long-term allogeneic hematopoietic cell transplantation survivors compared to a matched general population cohortHélène Schoemans, Kathy Goris, Steffen Fieuws, et al.
Annals of Hematology|May 4, 2021
Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registryTimothy Devos, Violaine Havelange, Koen Theunissen, et al.
The Lancet. Haematology|December 8, 2023
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trialAmer M Zeidan, Kiyoshi Ando, Odile Rauzy, et al.
Hematology (Amsterdam, Netherlands)|August 14, 2025
Real-world outcomes in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia treated with ponatinib - final 6-year results from a Belgian registryTimothy Devos, Dries Deeren, Koen Theunissen, et al.
Journal of Geriatric Oncology|August 10, 2025
Prospective comparison between geriatric assessment and clinical evaluation in 200 newly diagnosed older adults with multiple myelomaJolien Raddoux, Cindy Kenis, Anneleen Vanhellemont, et al.
Acta Clinica Belgica|February 23, 2017
Results from the Belgian mantle cell lymphoma registryVibeke Vergote, Ann Janssens, Marc André, et al.
Hemasphere|October 31, 2022
Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA ReportJon Salmanton-García, Francesco Marchesi, Andreas Glenthøj, et al.
Pageof 4